Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
FDA extends Exelixis zanzalintinib review by three months
Exelixis said the FDA extended its review of the company’s proposed zanzalintinib cancer drug by three months.
Exelixis FDA extends NDA review for zanzalintinib
The FDA extended review of Exelixis's NDA for zanzalintinib plus atezolizumab by three months, setting a new PDUFA date of March 3, 2027.